NCT01238393已完成不适用
A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Evidence of improvement measured by optical coherence tomography
研究概览
简要总结
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •symptomatic idiopathic epiretinal membrane
排除标准
- •vision worse than 6/18 and fit for surgery
- •prior vitreoretinal surgery or injection
- •any past or current form of retinal vein occlusion or neovascularization
- •age-related macular degeneration
- •other condition causing significant limitation of visual potential
研究组 & 干预措施
Ranibizumab
Experimental
('intravitreal ranibizumab' )
干预措施: intravitreal ranibizumab (Drug)
结局指标
主要结局
Evidence of improvement measured by optical coherence tomography
时间窗: 3 and 6 months
次要结局
- Subjective change in symptoms(3 and 6 months)
- Amsler grid improvement(3 and 6 months)
- Near visual acuity (Snellen)(3 and 6 months)
- Distance visual acuity (ETDRS)(3 and 6 months)
- Quality of life improvement(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel GrowthNeovascularizationNCT00685503National Eye Institute (NEI)1
已完成
1 期
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel GrowthMacular TelangiectasiaNCT00685854National Eye Institute (NEI)5
已完成
2 期
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)Proliferative Diabetic RetinopathyVitreous HemorrhageNCT00996437Jaeb Center for Health Research261
已完成
1 期
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationTelangiectasiaNCT00457145National Eye Institute (NEI)5
已完成
1 期
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel FormationTelangiectasiaNCT00457067National Eye Institute (NEI)5